| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Deltaline targets multiple receptors in the central nervous system. It is believed to act on the GABA-A receptor and the NMDA receptor. Its analgesic effects are likely mediated through these interactions. It is a toxin that can affect the nervous system, as it reduces sciatic nerve stimulation-induced compound muscle action potentials (CMAPs).
|
|---|---|
| ln Vitro |
In vitro, Deltaline has been shown to reduce sciatic nerve stimulation-induced compound muscle action potentials (CMAPs) in isolated lizard extensor digitorum longus muscle with an IC₅₀ that is not specified in the provided text. It has analgesic properties. Its activity on GABA-A and NMDA receptors can be studied in receptor binding or functional assays.
|
| ln Vivo |
In vivo, Deltaline has been shown to have potent anxiolytic and antidepressant effects in animal models, as well as anti-inflammatory and antioxidant properties. It has been used in research on pain relief. Its analgesic and potential therapeutic effects in neurological and psychiatric disorders are of interest.
|
| Enzyme Assay |
In vitro non-cell enzyme/receptor binding assays for Deltaline would involve measuring its affinity for the GABA-A and NMDA receptors. Radioligand binding studies using membrane preparations and labeled ligands would be used to determine its Ki values.
|
| Cell Assay |
In vitro cell-based assays for Deltaline would use neuronal cell lines to study its effects on receptor signaling. Electrophysiological techniques could be used to measure its effects on GABA-A or NMDA receptor-mediated currents. Its effects on cell viability and neuronal activity could also be assessed.
|
| Animal Protocol |
In vivo animal studies for Deltaline employ models of pain, anxiety, and depression. The compound is administered, and its effects are measured using behavioral tests such as the hot plate test, elevated plus maze, or forced swim test. Its anti-inflammatory effects can be studied in models of inflammation.
|
| ADME/Pharmacokinetics |
Deltaline has a molecular weight of 507.62 g/mol and a molecular formula of C₂₇H₄₁NO₈. It is a diterpenoid alkaloid. It is a solid. Detailed physicochemical and pharmacokinetic data are not widely published.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Deltaline is significant, as it is a toxin. It can cause neuromuscular blockade, as evidenced by its reduction of CMAPs. Its use in research requires careful handling and safety precautions. It is not intended for human therapeutic use.
|
| References | |
| Additional Infomation |
Deltaline is a diterpenoid alkaloid, tertiary alcohol, tertiary amine compound, acetate, cyclic acetal, and organic polycyclic compound. It is derived from the hydride of aconitane. Deltaline has been reported in Delphinium cheilanthum, Delphinium barbeyi, and other organisms with relevant data.
Deltaline is a diterpenoid alkaloid from Delphinium species with analgesic properties. It is believed to act on GABA-A and NMDA receptors. It has shown anxiolytic, antidepressant, and anti-inflammatory effects in animal models. It is a toxin and is not approved for clinical use; intended for research purposes only. |
| Molecular Formula |
C27H41NO8
|
|---|---|
| Molecular Weight |
507.6163
|
| Exact Mass |
507.283
|
| CAS # |
6836-11-9
|
| PubChem CID |
441728
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
597.6±50.0 °C at 760 mmHg
|
| Melting Point |
182-184℃
|
| Flash Point |
315.2±30.1 °C
|
| Vapour Pressure |
0.0±3.8 mmHg at 25°C
|
| Index of Refraction |
1.587
|
| LogP |
2.54
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
36
|
| Complexity |
979
|
| Defined Atom Stereocenter Count |
12
|
| SMILES |
CCN1C[C@@]2(CC[C@@H]([C@@]34[C@@H]2[C@@H]([C@@]5(C31)[C@]6(C[C@@H]([C@H]7C[C@@]4([C@@H]6[C@H]7OC)O)OC)OCO5)OC(=O)C)OC)C
|
| InChi Key |
DTTPWCNKTMQMTE-DZZCPBQSSA-N
|
| InChi Code |
InChI=1S/C27H41NO8/c1-7-28-12-23(3)9-8-17(32-5)26-20(23)21(36-14(2)29)27(22(26)28)25(34-13-35-27)11-16(31-4)15-10-24(26,30)19(25)18(15)33-6/h15-22,30H,7-13H2,1-6H3/t15-,16+,17+,18+,19+,20-,21+,22?,23+,24+,25-,26-,27-/m1/s1
|
| Chemical Name |
[(1R,2S,3S,4S,5R,6S,8R,12S,16R,19S,20R,21S)-14-ethyl-2-hydroxy-4,6,19-trimethoxy-16-methyl-9,11-dioxa-14-azaheptacyclo[10.7.2.12,5.01,13.03,8.08,12.016,20]docosan-21-yl] acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~197.00 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.92 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.92 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.92 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9700 mL | 9.8499 mL | 19.6998 mL | |
| 5 mM | 0.3940 mL | 1.9700 mL | 3.9400 mL | |
| 10 mM | 0.1970 mL | 0.9850 mL | 1.9700 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
